Polarean Imaging plc operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Polarean Imaging's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: POLX is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: POLX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
7 Day Return
GB Medical Equipment
1 Year Return
GB Medical Equipment
Return vs Industry: POLX exceeded the UK Medical Equipment industry which returned -11.7% over the past year.
Return vs Market: POLX exceeded the UK Market which returned -10% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Polarean Imaging's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StCan You Imagine How Jubilant Polarean Imaging's (LON:POLX) Shareholders Feel About Its 213% Share Price Gain?
1 month ago | Simply Wall StHere's Why We're Not Too Worried About Polarean Imaging's (LON:POLX) Cash Burn Situation
2 months ago | Simply Wall StAre Insiders Buying Polarean Imaging plc (LON:POLX) Stock?
Is Polarean Imaging undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate POLX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate POLX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: POLX is unprofitable, so we can't compare its PE Ratio to the GB Medical Equipment industry average.
PE vs Market: POLX is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate POLX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: POLX is overvalued based on its PB Ratio (12.8x) compared to the GB Medical Equipment industry average (3.5x).
How is Polarean Imaging forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Polarean Imaging has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Polarean Imaging's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Polarean Imaging competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Polarean Imaging performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: POLX is currently unprofitable.
Growing Profit Margin: POLX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: POLX is unprofitable, and losses have increased over the past 5 years at a rate of 26.6% per year.
Accelerating Growth: Unable to compare POLX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: POLX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-36.8%).
Return on Equity
High ROE: POLX has a negative Return on Equity (-50.88%), as it is currently unprofitable.
How is Polarean Imaging's financial position?
Financial Position Analysis
Short Term Liabilities: POLX's short term assets ($10.7M) exceed its short term liabilities ($2.1M).
Long Term Liabilities: POLX's short term assets ($10.7M) exceed its long term liabilities ($658.3K).
Debt to Equity History and Analysis
Debt Level: POLX is debt free.
Reducing Debt: POLX currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: POLX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: POLX has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 28.4% each year.
What is Polarean Imaging current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate POLX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate POLX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if POLX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if POLX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of POLX's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Clairis Hullihen (67 yo)
Mr. Clairis Richard Hullihen serves as the Chief Executive Officer of Polarean Imaging Plc and has been its Director since May 30, 2017. Mr. Hullihen has many years in medical imaging experience. He began ...
CEO Compensation Analysis
Compensation vs Market: Clairis's total compensation ($USD322.64K) is about average for companies of similar size in the UK market ($USD345.93K).
Compensation vs Earnings: Clairis's compensation has increased whilst the company is unprofitable.
|CEO & Director||no data||US$322.64k||1.81% |
|COO & Director||3.5yrs||US$211.88k||0.29% |
|Non-Executive Director||0.42yr||no data||0.22% |
|Independent Chairman||0.75yr||US$54.04k||1.5% |
|Non-Executive Director||3.5yrs||US$64.04k||no data|
Experienced Board: POLX's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 41.5%.
Polarean Imaging plc's company bio, employee growth, exchange listings and data sources
- Name: Polarean Imaging plc
- Ticker: POLX
- Exchange: AIM
- Founded: 2016
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: UK£110.897m
- Shares outstanding: 161.89m
- Website: https://www.polarean.com
Number of Employees
- Polarean Imaging plc
- 2500 Meridian Parkway
- Suite 175
- North Carolina
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|POLX||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Mar 2018|
|PLLW.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Mar 2018|
Polarean Imaging plc operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The company engages in the development and commercial...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/26 20:15|
|End of Day Share Price||2020/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.